Nuvectis Pharma Inc (NVCT)

$9.67 +0.36 (3.87%)
Market Cap 246.96M
Revenue (ttm) 0.00
Net Income (ttm) -26.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 38,100
Avg Vol 83,288
Day's Range N/A - N/A
Shares Out 26.53M
Stochastic %K 21%
Beta -0.07
Analysts Strong Sell
Price Target $16.25

Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 614 3150
Address:
1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, United States
UNLV
UNLV Jun. 4 at 1:53 PM
$NVCT is my top pick by wide margin but like phase 3 drugs that look promising small caps VNDA - phase 3 prevents vomiting when taking obesity drugs GLSI - phase 3 prevents breast cancer recurrence
0 · Reply
UNLV
UNLV May. 22 at 1:41 PM
$NVCT can’t get past this…CEO talked of raising capital at MUCH HIGHER prices around successful 1b Mono therapy - 41k patients Combo therapy - 30k patients I’ll be selling OTM covered calls much higher prices
1 · Reply
UNLV
UNLV May. 21 at 6:12 PM
$NVCT be prepared for higher prices as CEO said they expect to raise additional capital at HIGHER prices with successful 1b. I’m big the Tagrisso combo projecting mono therapies as Free-Roll opportunities. Preclinical combo tested better efficacy than either drug alone…with some talk of possible total tumor shrinkage
0 · Reply
UNLV
UNLV May. 21 at 2:26 PM
$NVCT I focus on insider trading with small caps. Huge vote of confidence buying stocks opposed to granting of stock options - PAY ATTENTION
0 · Reply
UNLV
UNLV May. 20 at 10:26 PM
$NVCT very large 154,770 INSIDER share purchase 10/29/2026 came after it was evident NXP900 had 90% inhibition in humans during 1b trial that started August. Lead researcher acknowledged inhibition in humans during November presentation
0 · Reply
UNLV
UNLV May. 20 at 3:27 PM
$NVCT Everything changes Everything is connected PAY ATTENTION https://x.com/dalvinvarnado/status/2047017194492678366?s=46
1 · Reply
UNLV
UNLV May. 19 at 4:23 PM
$NVCT I’m treating the stock like a small business opportunity. Huge insider ownership and insider purchases last year set this stock way apart Everything changes Everything is connected PAY ATTENTION
1 · Reply
Andreagomirato
Andreagomirato May. 19 at 1:09 PM
$NVCT can you guys tell me what you think about this company?
3 · Reply
BioTrade2
BioTrade2 May. 18 at 2:26 AM
$NVCT something extremely off here. DoodadDoc and seedy updated 13F info from so many funds and 0 mentions of nvct. 0. Zip.
1 · Reply
BioTrade2
BioTrade2 May. 16 at 1:47 AM
$NVCT Wainwright conference next week. Will they take questions or only do a 20 min presentation?
0 · Reply
Latest News on NVCT
Nuvectis Pharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 9:00 AM EDT - 16 days ago

Nuvectis Pharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

May 14, 2026, 7:30 AM EDT - 21 days ago

Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Nuvectis Pharma Slides: Corporate presentation

May 11, 2026, 7:00 AM EDT - 24 days ago

Nuvectis Pharma Slides: Corporate presentation

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

May 5, 2026, 7:30 AM EDT - 4 weeks ago

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

Nuvectis Pharma Earnings release: Q1 2026

May 5, 2026, 7:30 AM EDT - 4 weeks ago

Nuvectis Pharma Earnings release: Q1 2026

Nuvectis Pharma Quarterly report: Q1 2026

May 5, 2026, 7:30 AM EDT - 4 weeks ago

Nuvectis Pharma Quarterly report: Q1 2026

Nuvectis Pharma Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Nuvectis Pharma Proxy statement: Proxy filing

Nuvectis Pharma Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Nuvectis Pharma Proxy statement: Proxy filing

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Mar 31, 2026, 8:00 AM EDT - 2 months ago

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Nuvectis Pharma management to meet with Maxim

2026-03-19T19:35:17.000Z - 2 months ago

Nuvectis Pharma management to meet with Maxim

Nuvectis Pharma Slides: Corporate presentation

Mar 13, 2026, 7:00 AM EDT - 2 months ago

Nuvectis Pharma Slides: Corporate presentation

Nuvectis Pharma files $150M mixed securities shelf

2026-02-13T21:05:11.000Z - 3 months ago

Nuvectis Pharma files $150M mixed securities shelf

Nuvectis Pharma Registration statement: Registration Filing

Feb 13, 2026, 7:00 AM EST - 3 months ago

Nuvectis Pharma Registration statement: Registration Filing

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Feb 11, 2026, 7:30 AM EST - 4 months ago

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Nuvectis Pharma Earnings release: Q4 2025

Feb 11, 2026, 7:00 AM EST - 4 months ago

Nuvectis Pharma Earnings release: Q4 2025

Nuvectis Pharma Annual report: Q4 2025

Feb 11, 2026, 7:00 AM EST - 4 months ago

Nuvectis Pharma Annual report: Q4 2025

Nuvectis Pharma announces initiation of Phase 1b study of NXP900

2025-12-17T12:13:26.000Z - 6 months ago

Nuvectis Pharma announces initiation of Phase 1b study of NXP900

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Dec 17, 2025, 7:00 AM EST - 6 months ago

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Nuvectis Pharma Transcript: KOL Event

Dec 2, 2025, 8:00 AM EST - 6 months ago

Nuvectis Pharma Transcript: KOL Event

Nuvectis Pharma Slides: KOL Event

Dec 2, 2025, 8:00 AM EST - 6 months ago

Nuvectis Pharma Slides: KOL Event

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Nov 25, 2025, 8:00 AM EST - 6 months ago

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Nuvectis Pharma Earnings release: Q3 2025

Nov 4, 2025, 4:00 PM EST - 7 months ago

Nuvectis Pharma Earnings release: Q3 2025

Nuvectis Pharma Quarterly report: Q3 2025

Nov 4, 2025, 4:00 PM EST - 7 months ago

Nuvectis Pharma Quarterly report: Q3 2025

Nuvectis Pharma reports Q3 EPS (44c), consensus (25c)

2025-11-04T13:20:44.000Z - 7 months ago

Nuvectis Pharma reports Q3 EPS (44c), consensus (25c)

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 4, 2025, 8:15 AM EST - 7 months ago

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Nuvectis Pharma reports Q3 net loss $7.5M vs $4.2M last year

2025-11-04T12:36:25.000Z - 7 months ago

Nuvectis Pharma reports Q3 net loss $7.5M vs $4.2M last year

Nuvectis Pharma provides highlights from NXP900 poster presentations

2025-10-27T12:17:17.000Z - 7 months ago

Nuvectis Pharma provides highlights from NXP900 poster presentations

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 16, 2025, 8:00 AM EDT - 8 months ago

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Nuvectis Pharma appoints Juan Sanchez to board of directors

2025-09-25T12:05:11.000Z - 9 months ago

Nuvectis Pharma appoints Juan Sanchez to board of directors

Nuvectis Pharma Slides: Corporate Presentation

Sep 5, 2025, 7:00 AM EDT - 9 months ago

Nuvectis Pharma Slides: Corporate Presentation

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:30 AM EDT - 9 months ago

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Nuvectis Pharma Transcript: Status Update

Aug 12, 2025, 8:30 AM EDT - 10 months ago

Nuvectis Pharma Transcript: Status Update

Nuvectis Pharma Press release: Status Update

Aug 12, 2025, 8:30 AM EDT - 10 months ago

Nuvectis Pharma Press release: Status Update

Nuvectis Pharma initiates NXP900 program

2025-08-11T21:10:25.000Z - 10 months ago

Nuvectis Pharma initiates NXP900 program

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

Aug 11, 2025, 4:30 PM EDT - 10 months ago

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

Nuvectis Pharma Quarterly report: Q2 2025

Aug 5, 2025, 9:00 AM EDT - 10 months ago

Nuvectis Pharma Quarterly report: Q2 2025

Nuvectis Pharma Earnings release: Q2 2025

Aug 5, 2025, 9:00 AM EDT - 10 months ago

Nuvectis Pharma Earnings release: Q2 2025

Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year

2025-08-05T11:35:18.000Z - 10 months ago

Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 5, 2025, 7:30 AM EDT - 10 months ago

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

Nuvectis Pharma price target lowered to $10 from $15 at H.C. Wainwright

2025-08-04T14:01:05.000Z - 10 months ago

Nuvectis Pharma price target lowered to $10 from $15 at H.C. Wainwright

Nuvectis Pharma provides final clinical data update from NXP800 Phase 1b study

2025-07-31T11:50:58.000Z - 11 months ago

Nuvectis Pharma provides final clinical data update from NXP800 Phase 1b study

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

Jul 31, 2025, 7:45 AM EDT - 11 months ago

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

Nuvectis Pharma’s NXP900 shows positive drug interaction results in lung cancer

2025-07-08T12:15:12.000Z - 11 months ago

Nuvectis Pharma’s NXP900 shows positive drug interaction results in lung cancer

Nuvectis Pharma Slides: Corporate Presentation

Jun 13, 2025, 11:00 AM EDT - 1 year ago

Nuvectis Pharma Slides: Corporate Presentation

Nuvectis Pharma Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 10:30 AM EDT - 1 year ago

Nuvectis Pharma Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

May 16, 2025, 4:35 PM EDT - 1 year ago

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

Nuvectis Pharma Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Nuvectis Pharma Quarterly report: Q1 2025

Nuvectis Pharma Earnings release: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Nuvectis Pharma Earnings release: Q1 2025

Nuvectis Pharma reports Q1 EPS (27c) vs (25c) last year

2025-05-06T12:17:22.000Z - 1 year ago

Nuvectis Pharma reports Q1 EPS (27c) vs (25c) last year

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

Nuvectis Pharma price target raised to $15 from $11 at H.C. Wainwright

2025-04-30T10:12:04.000Z - 1 year ago

Nuvectis Pharma price target raised to $15 from $11 at H.C. Wainwright

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Apr 29, 2025, 4:25 PM EDT - 1 year ago

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Nuvectis Pharma Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Proxy statement: Proxy Filing

Nuvectis Pharma Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Proxy statement: Proxy Filing

Nuvectis Pharma initiated with a Buy at Maxim

2025-04-02T11:45:09.000Z - 1 year ago

Nuvectis Pharma initiated with a Buy at Maxim

Nuvectis Pharma initiated with a Buy at Laidlaw

2025-03-17T07:30:05.000Z - 1 year ago

Nuvectis Pharma initiated with a Buy at Laidlaw

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Mar 14, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Nuvectis announces new publication of research study on NXP900, osimertinib

2025-03-04T13:22:12.000Z - 1 year ago

Nuvectis announces new publication of research study on NXP900, osimertinib

Nuvectis Pharma initiated with a Buy at Lucid Capital

2025-02-26T12:10:44.000Z - 1 year ago

Nuvectis Pharma initiated with a Buy at Lucid Capital

Nuvectis Pharma price target lowered to $11 from $21 at H.C. Wainwright

2025-02-25T16:37:08.000Z - 1 year ago

Nuvectis Pharma price target lowered to $11 from $21 at H.C. Wainwright

Nuvectis Pharma Annual report: Q4 2024

Feb 25, 2025, 9:30 AM EST - 1 year ago

Nuvectis Pharma Annual report: Q4 2024

Nuvectis Pharma Earnings release: Q4 2024

Feb 25, 2025, 9:30 AM EST - 1 year ago

Nuvectis Pharma Earnings release: Q4 2024

Nuvectis Pharma reports FY24 EPS ($1.11) vs. ($1.43) last year

2025-02-25T13:06:50.000Z - 1 year ago

Nuvectis Pharma reports FY24 EPS ($1.11) vs. ($1.43) last year

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

Feb 7, 2025, 8:30 AM EST - 1 year ago

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Feb 5, 2025, 9:01 AM EST - 1 year ago

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Feb 4, 2025, 4:05 PM EST - 1 year ago

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 5, 2024, 7:00 AM EST - 1 year ago

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Nuvectis Pharma Quarterly report: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Nuvectis Pharma Quarterly report: Q3 2024

Nuvectis Pharma Earnings release: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Nuvectis Pharma Earnings release: Q3 2024

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Oct 28, 2024, 8:21 AM EDT - 1 year ago

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

DRUG

Nuvectis Pharma Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 12:00 PM EDT - 1 year ago

Nuvectis Pharma Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Nuvectis Pharma Quarterly report: Q2 2024

Aug 6, 2024, 8:45 AM EDT - 1 year ago

Nuvectis Pharma Quarterly report: Q2 2024

Nuvectis Pharma Earnings release: Q2 2024

Aug 6, 2024, 8:45 AM EDT - 1 year ago

Nuvectis Pharma Earnings release: Q2 2024

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 6, 2024, 8:28 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

May 16, 2024, 8:30 AM EDT - 2 years ago

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

May 7, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

Nuvectis Pharma Quarterly report: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Nuvectis Pharma Quarterly report: Q1 2024

Nuvectis Pharma Earnings release: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Nuvectis Pharma Earnings release: Q1 2024

Nuvectis Pharma Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Proxy statement: Proxy Filing

Nuvectis Pharma Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Proxy statement: Proxy Filing

Nuvectis Pharma Slides: Corporate Presentation

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Nuvectis Pharma Slides: Corporate Presentation

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Apr 8, 2024, 8:30 AM EDT - 2 years ago

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Nuvectis Pharma to Present at the 36th Annual Roth Conference

Mar 15, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma to Present at the 36th Annual Roth Conference

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Mar 14, 2024, 9:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

Mar 5, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

Nuvectis Pharma Earnings release: Q4 2023

Mar 5, 2024, 7:00 AM EST - 2 years ago

Nuvectis Pharma Earnings release: Q4 2023

Nuvectis Pharma Annual report: Q4 2023

Mar 5, 2024, 7:00 AM EST - 2 years ago

Nuvectis Pharma Annual report: Q4 2023

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Feb 9, 2024, 8:32 AM EST - 2 years ago

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Feb 9, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 8, 2023, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Nuvectis Pharma Quarterly report: Q3 2023

Nov 8, 2023, 7:00 AM EST - 2 years ago

Nuvectis Pharma Quarterly report: Q3 2023

Nuvectis Pharma Earnings release: Q3 2023

Nov 8, 2023, 7:00 AM EST - 2 years ago

Nuvectis Pharma Earnings release: Q3 2023

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

Sep 25, 2023, 7:30 PM EDT - 2 years ago

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Sep 21, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Nuvectis Pharma Transcript: Status Update

Sep 14, 2023, 7:00 AM EDT - 2 years ago

Nuvectis Pharma Transcript: Status Update

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

Aug 17, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 9, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

Nuvectis Pharma Quarterly report: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Quarterly report: Q2 2023

Nuvectis Pharma Earnings release: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Earnings release: Q2 2023

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 15, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

May 10, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

Nuvectis Pharma Quarterly report: Q1 2023

May 10, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Quarterly report: Q1 2023

Nuvectis Pharma Earnings release: Q1 2023

May 10, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Earnings release: Q1 2023

Nuvectis Pharma Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Proxy statement: Proxy Filing

Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 27, 2023, 10:14 AM EDT - 3 years ago

Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma

Apr 10, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma

Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

Mar 17, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

Nuvectis Pharma Registration statement: Registration Filing

Mar 17, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Registration statement: Registration Filing

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

Mar 10, 2023, 8:00 AM EST - 3 years ago

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights

Mar 7, 2023, 8:00 AM EST - 3 years ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights

Nuvectis Pharma Earnings release: Q4 2022

Mar 7, 2023, 7:00 AM EST - 3 years ago

Nuvectis Pharma Earnings release: Q4 2022

Nuvectis Pharma Annual report: Q4 2022

Mar 7, 2023, 7:00 AM EST - 3 years ago

Nuvectis Pharma Annual report: Q4 2022

FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

Dec 1, 2022, 8:00 AM EST - 3 years ago

FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights

Nov 8, 2022, 8:00 AM EST - 3 years ago

Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights

UNLV
UNLV Jun. 4 at 1:53 PM
$NVCT is my top pick by wide margin but like phase 3 drugs that look promising small caps VNDA - phase 3 prevents vomiting when taking obesity drugs GLSI - phase 3 prevents breast cancer recurrence
0 · Reply
UNLV
UNLV May. 22 at 1:41 PM
$NVCT can’t get past this…CEO talked of raising capital at MUCH HIGHER prices around successful 1b Mono therapy - 41k patients Combo therapy - 30k patients I’ll be selling OTM covered calls much higher prices
1 · Reply
UNLV
UNLV May. 21 at 6:12 PM
$NVCT be prepared for higher prices as CEO said they expect to raise additional capital at HIGHER prices with successful 1b. I’m big the Tagrisso combo projecting mono therapies as Free-Roll opportunities. Preclinical combo tested better efficacy than either drug alone…with some talk of possible total tumor shrinkage
0 · Reply
UNLV
UNLV May. 21 at 2:26 PM
$NVCT I focus on insider trading with small caps. Huge vote of confidence buying stocks opposed to granting of stock options - PAY ATTENTION
0 · Reply
UNLV
UNLV May. 20 at 10:26 PM
$NVCT very large 154,770 INSIDER share purchase 10/29/2026 came after it was evident NXP900 had 90% inhibition in humans during 1b trial that started August. Lead researcher acknowledged inhibition in humans during November presentation
0 · Reply
UNLV
UNLV May. 20 at 3:27 PM
$NVCT Everything changes Everything is connected PAY ATTENTION https://x.com/dalvinvarnado/status/2047017194492678366?s=46
1 · Reply
UNLV
UNLV May. 19 at 4:23 PM
$NVCT I’m treating the stock like a small business opportunity. Huge insider ownership and insider purchases last year set this stock way apart Everything changes Everything is connected PAY ATTENTION
1 · Reply
Andreagomirato
Andreagomirato May. 19 at 1:09 PM
$NVCT can you guys tell me what you think about this company?
3 · Reply
BioTrade2
BioTrade2 May. 18 at 2:26 AM
$NVCT something extremely off here. DoodadDoc and seedy updated 13F info from so many funds and 0 mentions of nvct. 0. Zip.
1 · Reply
BioTrade2
BioTrade2 May. 16 at 1:47 AM
$NVCT Wainwright conference next week. Will they take questions or only do a 20 min presentation?
0 · Reply
WallStWireAds
WallStWireAds May. 14 at 11:33 AM
$NVCT https://www.globenewswire.com/news-release/2026/05/14/3294811/0/en/Nuvectis-Pharma-Inc-To-Participate-in-the-H-C-Wainwright-4th-Annua
0 · Reply
STACKD0E
STACKD0E May. 13 at 3:27 PM
$NVCT $CCCC $IMUX
1 · Reply
kkorotney
kkorotney May. 13 at 3:07 PM
$NVCT nice to see some activity in options. Also decent volume this morning.
0 · Reply
kkorotney
kkorotney May. 12 at 5:00 PM
$NVCT bought 12 $10 Oct Calls for $3.20 and than an hour later someone bought 500 of them for $3.90... Lets go!
1 · Reply
buyandsold
buyandsold May. 8 at 4:20 PM
$NVCT With this kind of price action you'd almost think they're going to cure cancer. Oh yeah they are.
1 · Reply
PenkeInvesting
PenkeInvesting May. 6 at 11:49 PM
Fundamental analysis of $NVCT (Nuvectis Pharma, Inc.) based on financial data and reported results. #NVCT #Nuvectis
0 · Reply
UNLV
UNLV May. 5 at 1:42 PM
$NVCT latest from AstraZeneca 45% of Tagrisso resistance remains unknown with info from clinical trials. AstraZeneca believes 80-85% of unknown resistance is bypass through SRC. NXP900 effectively shutdowns this resistance bypass
1 · Reply
UNLV
UNLV May. 5 at 1:31 PM
$NVCT takeaway today’s earnings company continues minimizing losses -6M last quarter. 13 employees and research lead by Ashier Unciti-Broceta department University Edinburgh cost savings are colossal CEO said 1b data update this summer I’m saying insider buying a prelude and Tagrisso combo will set up massive Free-Roll opportunity on rest of 1b
0 · Reply
WallStWireAds
WallStWireAds May. 5 at 11:33 AM
$NVCT https://www.globenewswire.com/news-release/2026/05/05/3287554/0/en/Nuvectis-Pharma-Inc-Reports-First-Quarter-2026-Financial-Results-a
0 · Reply
WallStWireAds
WallStWireAds May. 4 at 2:52 PM
$NVCT https://finance.yahoo.com/markets/stocks/articles/insider-stock-buying-reaches-us-103630079.html
0 · Reply
UNLV
UNLV May. 4 at 1:58 PM
$NVCT Still no insider selling by four largest holders in control of 9.75M shares. Clear indication early 1b data looks promising
1 · Reply
BioTrade2
BioTrade2 Apr. 22 at 6:35 PM
$NVCT 2 new AACR posters up on the sure now https://nuvectis.com/nxp900-publications/
1 · Reply